Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Oncolytics Biotech Inc ONCY


Primary Symbol: T.ONC

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by Quentin30on Dec 02, 2024 1:09pm
74 Views
Post# 36341041

RE:Weekend update , hello all

RE:Weekend update , hello allInteresting tome Canaduh... the PC trial could indeed lead to a partnership,... but it's worth remembering that the oft touted Phase III ready mBC co-therapy, INCLUDES Chemo... and

It is likely that this very aspect of the treatment, is what is holding back interest. Patients will still be on chemo... and if they survive longer, will be on chemo for longer... it's not the best proposition really.

or do you have some better explanation as to why after 7+ years of stating that ONCY will begin a Phase III for mBC with a partner, that there is NO partner.. How much longer do they need to assess ONCY's data...

ONCY could do a reverse split and run one Phase III themselves, and I would guess they will go for PC, meaning mBC will never see the light of day...
<< Previous
Bullboard Posts
Next >>